Skip to main content

Drug Interactions between arformoterol and Diamox

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

acetaZOLAMIDE arformoterol

Applies to: Diamox (acetazolamide) and arformoterol

MONITOR: Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.

MANAGEMENT: Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.

References

  1. Lipworth BJ, McDevitt DG, Struthers AD "Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol." Am J Med 86 (1989): 653-7
  2. "Product Information. Proventil (albuterol)." Schering Corporation PROD (2002):
  3. "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals PROD (2001):
  4. "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim PROD (2001):
  5. "Product Information. Brovana (arformoterol)." Sepracor Inc (2006):
  6. "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals (2011):
  7. "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline (2013):
  8. "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
View all 8 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer